by Phil Gutis for Being Patient: The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its Alzheimer’s drug, aducanumab. The company said it expects patients to……
Biogen Given Green Light to Relaunch Aducanumab Study on Alzheimer’s Trial Participants
by Phil Gutis for Being Patient: The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its Alzheimer’s drug, aducanumab. The company said it expects patients to……